CryoPort (NASDAQ:CYRX) Sets New 1-Year High – Time to Buy?

CryoPort, Inc. (NASDAQ:CYRX)’s stock price reached a new 52-week high on Thursday . The company traded as high as $14.68 and last traded at $14.6340, with a volume of 36519 shares changing hands. The stock had previously closed at $14.02.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on CYRX shares. KeyCorp raised their price target on CryoPort from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. Wall Street Zen upgraded shares of CryoPort from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. Needham & Company LLC raised their target price on shares of CryoPort from $13.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Craig Hallum assumed coverage on shares of CryoPort in a research report on Monday, March 30th. They issued a “buy” rating and a $15.00 target price for the company. Finally, Weiss Ratings raised shares of CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 6th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $14.69.

CryoPort Trading Up 3.9%

The firm has a 50-day moving average of $10.68 and a two-hundred day moving average of $9.77. The firm has a market capitalization of $733.92 million, a P/E ratio of 10.97 and a beta of 1.75.

CryoPort (NASDAQ:CYRX) last released its earnings results on Monday, May 4th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The business had revenue of $47.80 million during the quarter, compared to the consensus estimate of $44.86 million. CryoPort had a net margin of 41.57% and a negative return on equity of 7.92%. On average, sell-side analysts anticipate that CryoPort, Inc. will post -0.74 EPS for the current fiscal year.

Insider Buying and Selling at CryoPort

In related news, CEO Jerrell Shelton sold 7,918 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $8.00, for a total transaction of $63,344.00. Following the sale, the chief executive officer owned 1,054,501 shares of the company’s stock, valued at $8,436,008. This trade represents a 0.75% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Mark W. Sawicki sold 3,235 shares of the company’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $8.00, for a total value of $25,880.00. Following the completion of the transaction, the insider directly owned 103,697 shares of the company’s stock, valued at approximately $829,576. The trade was a 3.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 59,939 shares of company stock worth $471,183 over the last quarter. Corporate insiders own 10.00% of the company’s stock.

Institutional Trading of CryoPort

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Basepoint Wealth LLC acquired a new stake in CryoPort during the 4th quarter worth approximately $34,000. Whittier Trust Co. of Nevada Inc. acquired a new position in shares of CryoPort during the third quarter worth $53,000. Tower Research Capital LLC TRC lifted its holdings in shares of CryoPort by 300.1% during the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock worth $44,000 after purchasing an additional 4,375 shares during the period. AlphaQuest LLC bought a new stake in shares of CryoPort in the third quarter worth $79,000. Finally, Quadrature Capital Ltd acquired a new stake in CryoPort in the fourth quarter valued at $97,000. 92.90% of the stock is currently owned by institutional investors.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.